Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial()

BACKGROUND AND PURPOSE: Addition of carbogen and nicotinamide (hypoxia-modifying agents) to radiotherapy improves the survival of patients with high risk bladder cancer. The study investigated whether histopathological tumour features and putative hypoxia markers predicted benefit from hypoxia modif...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Eustace, Amanda, Irlam, Joely J., Taylor, Janet, Denley, Helen, Agrawal, Shailesh, Choudhury, Ananya, Ryder, David, Ord, Jonathan J., Harris, Adrian L., Rojas, Ana M., Hoskin, Peter J., West, Catharine M.L.
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier Scientific Publishers 2013
Assuntos:
Phase III randomised trial
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3885794/
https://ncbi.nlm.nih.gov/pubmed/23773411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.radonc.2013.05.017
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares